CorMedix Inc. Common Stock (CRMD)
Stock · NASDAQ · Health Care
$7.28as of 10/16/2026
Price chart
Active signals
CRMD Signal Track Record
How signals performed across all stocks →What CRMD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | +8.1% | 65% | September 18, 2026 |
| Bollinger Band Breakout | 29 | +3.0% | 62% | August 19, 2026 |
| Bollinger Band Breakdown | 21 | +11.3% | 71% | October 2, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -3.5% | 47% | September 8, 2026 |
| Any 20-session window (baseline) | +1.2% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company,…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 191
- Website
- cormedix.com/
Fundamentals
- 1-day range
- $7.24$7.44
- Market cap
- $589.17M
- P/E (trailing)
- 3.11
- P/E (forward)
- 20.74
- EPS (trailing)
- $2.10
- Dividend yield
- —
- Beta
- 1.46
- Avg. volume
- 1.11M
- Dividend pay date
- March 26, 2019
How CorMedix Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 25, 2025 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
CorMedix Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CRMDCorMedix Inc. Common Stock$7.26▼ 2.68%Market cap $589.17MP/E 3.11$6.13$13.02
- ALTAltimmune Inc. Common Stock$2.2▼ 6.78%Market cap $585.37MP/E —$2.56$6.44
- CTNMContineum Therapeutics Inc. Class A Common Stock$7.08▼ 10.38%Market cap $577.48MP/E —$7.72$17.79
- MPLTMapLight Therapeutics Inc. Common Stock$7.7▼ 3.99%Market cap $602.19MP/E —$8.7$40.43
- CBIOCrescent Biopharma Inc. Common Stock$11.84▼ 5.13%Market cap $610.27MP/E —$8.72$27.41
- ARVNArvinas Inc. Common Stock$6.97▼ 2.65%Market cap $567.55MP/E 50.48$6.74$14.51
- NVCTNuvectis Pharma Inc. Common Stock$18.6▼ 1.74%Market cap $613.51MP/E —$5.55$29.28
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CRMD CorMedix Inc. Common Stock | $589.17M | 3.11 | $7.26 | ▼ 2.68% | $6.13$13.02 |
| ALT Altimmune Inc. Common Stock | $585.37M | — | $2.2 | ▼ 6.78% | $2.56$6.44 |
| CTNM Contineum Therapeutics Inc. Class A Common Stock | $577.48M | — | $7.08 | ▼ 10.38% | $7.72$17.79 |
| MPLT MapLight Therapeutics Inc. Common Stock | $602.19M | — | $7.7 | ▼ 3.99% | $8.7$40.43 |
| CBIO Crescent Biopharma Inc. Common Stock | $610.27M | — | $11.84 | ▼ 5.13% | $8.72$27.41 |
| ARVN Arvinas Inc. Common Stock | $567.55M | 50.48 | $6.97 | ▼ 2.65% | $6.74$14.51 |
| NVCT Nuvectis Pharma Inc. Common Stock | $613.51M | — | $18.6 | ▼ 1.74% | $5.55$29.28 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Actinium Pharmaceuticals Appoints Dr. Matt David As CFObenzinga · 10/15/2026
- CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?Yahoo · 10/8/2026
- Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15Benzinga · 9/23/2026
Insider Activity
Insider Actions →- Janet Dillione · September 18, 2026 · Option Exercise48.9K
- Susan Blum · August 29, 2026 · Tax Withholding8.4K @ $8.3
- Elizabeth Hurlburt · August 29, 2026 · Tax Withholding8.1K @ $8.3
- Kaufman Beth Zelnick · August 29, 2026 · Tax Withholding8.4K @ $8.3
Institutional Ownership
March 31, 2026
- Total shares held
- 42.58M
- Total value held
- $285.91M
- Institutional holders
- 184
- Unknown6.27M
- Unknown5.97M
- Unknown3.13M
- Unknown2.19M
- Unknown1.89M
- Unknown1.89M
- Unknown1.82M
- Unknown1.54M
- Unknown1.21M
- Unknown850.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
CRMD: No direct news in the last week
Recent headlines involve Actinium Pharmaceuticals, not CorMedix Inc. There are no events that directly affect CRMD’s operations or market position. Investors can continue to monitor CRMD’s own performance and broader market conditions.
CRMD: No direct news in the last week. Recent headlines involve Actinium Pharmaceuticals, not CorMedix Inc. There are no events that directly affect CRMD’s operations or market position. Investors can continue to monitor CRMD’s own performance and broader market conditions.